Stocks · News reference
ANI Pharmaceuticals Plans To Appeal Judge Sheldon K. Rennie's Decision To Deny ANI's Post-Trial Motions For New Trial, Judgement; Co. Seeks To Recover Assets' Value Sold to CG Oncology Under 2010 Deal
ANI Pharmaceuticals, Inc. (NASDAQ:ANIP) (ANI or the Company) today announced that Judge Sheldon K. Rennie, on July 16, 2026, denied ANI’s post-trial motions for a new trial and judgment as a matter of law. ANI intends
Reference Details
Connected Markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- benzinga
- Observed
- Checked
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading
Related Headlines
ANI Pharmaceuticals To Present Data From SYNCHRONICITY Phase 4 Clinical Trial Of Fluocinolone Acetonide Intravitreal Implant In Patients With Chronic Non-Infectious Uveitis Affecting The Posterior Segment Of The Eye In Oral Presentation During Uveitis Subspecialty Day 2026 At The American Academy Of Ophthalmology Meeting On October 9
Oppenheimer Initiates Coverage On ANI Pharmaceuticals with Perform Rating, Announces Price Target of $85
Oppenheimer analyst Les Sulewski initiates coverage on ANI Pharmaceuticals (NASDAQ:ANIP) with a Perform rating and announces Price Target of $85.
ANI Pharmaceuticals Receives Final FDA Approval Of Its Abbreviated New Drug Application For Everolimus Tablets For Oral Suspension
Approval for Everolimus Tablets for Oral Suspension 2mg, 3mg and 5mg. ANI’s Everolimus Tablets for Oral Suspension are the generic version of the reference listed drug (RLD) Afinitor Disperz®."The FDA approval of
CG Oncology to Present at Upcoming Investor Conferences in September
CG Oncology announced that its CEO Arthur Kuan will participate in fireside chat presentations at the Cantor Fitzgerald Global Healthcare Conference on September 9, 2026, and the Morgan Stanley Global Healthcare Conference on September 14, 2026. The company is a late-stage clinical biopharmaceutical firm developing immunotherapies for bladder cancer treatment.
RBC Capital Maintains Outperform on CG Oncology, Lowers Price Target to $79